Inhibition of nitric oxide synthase by L-NAME improves ventricular performance in streptozotocin-diabetic rats

Journal of Molecular and Cellular Cardiology

Volumn 29, Issue 9, 1997, Pages 2393-2402

  Smith, Jacquelyn M ^a   Paulson, Dennis J ^a   Romano, Fred D ^a  

^a MIDWESTERN UNIVERSITY   (United States)

Author keywords

cNOS; Dobutamine; iNOS; L NAME; Myocardial contractility; Myocytes; Nitric oxide; Streptozotocin diabetic rat; adrenergic agonists

Indexed keywords

ARGININE METHYL ESTER; DOBUTAMINE; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA FLOW; ARTICLE; ENZYME INHIBITION; HEART LEFT VENTRICLE PERFORMANCE; HEART OUTPUT; HEART RATE; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; STREPTOZOCIN DIABETES; SYSTOLIC BLOOD PRESSURE;

ANIMALIA;

EID: 0031238848     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmcc.1997.0474     Document Type: Article

References (59)

1. AMRANI M, O'SHEA J, ALLEN NJ, HARDING SE, JAYAKUMAR J, PEPPER JR, MONCADA S, YACOUB MH, 1992. Role of basal release of nitric oxide on coronary flow and mechanical performance of the isolated rat heart. J Physiol 456: 681-687.
2. BALLIGAND JL, UNGUREANU D, KELLY RA, KOBZIK L, PIMENTAL D, MICHEL T, SMITH TW, 1993a. Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium. J Clin Invest 91: 2314-2319.
3. BALLIGAND JL, KELLY RA, MARSDEN PA, SMITH TW, MICHEL T, 1993b. Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acad Sci USA 90: 347-351.
4. BALLIGAND JL, UNGUREANU-LONGROIS D, SIMMONS WW, PIMENTAL D, MALINSKI TA, KAPTURCZAK M, TAHA Z, LOWENSTEIN CJ, DAVIDOFF AJ, KELLY RA, SMITH TW, MICHEL T, 1994. Cytokine-inducible nitric oxide synthase (iNOS) expression in cardiac myocytes. J Biol Chem 269: 27580-27588.
5. BALLIGAND JL, KOBZIK L, HAN X, KAYE DM, BELHASSEN L, O'HARA DS, KELLY RA, SMITH TW, MICHEL T, 1995. Nitric oxide-dependent parasympathetic signaling is due to activation of constitutive endothelial (type III) nitric oxide synthase in cardiac myocytes. J Biol Chem 270: 14582-14586.
6. BANK N, AYNEDJIAN HS, 1993. Role of EFRF (nitric oxide) in diabetic renal hyperfiltration. Kidney Internat 43: 1306-1312.
7. BELDER AJ, RADOMSKI MW, MARTIN JF, MONCADA S, 1995. Nitric oxide and the pathogenesis of heart muscle disease. Eur J Clin Invest 25: 1-8.
8. BRADY AJB, POOLE-WILSON PA, HARDING SE, WARREN JB, 1992. Nitric oxide production within cardiac myocytes reduces their contractility in endotoxemia. Am J Physiol 263: H1963-H1966.
9. BRADY AJB, WARREN JB, POOLE-WILSON PA, WILLIAMS TJ, HARDING SE, 1993. Nitric oxide attenuates cardiac myocytes contraction. Am J Physiol 265: H176-H182.
10. BUCZEK-THOMAS J, MILLER TB, 1995. Cyclic GMP accumulation in normal and diabetic primary culture adult rat ventricular cardiomyocytes: a minor role for nitric oxide in phosphorylase activation. Cell Signal 7: 591-598.
11. CORBETT JA, TILTON RG, CHANG K, HASAN KS, IDO Y, WANG JL, SWEETLAND MA, LANCASTER JR, WILLIAMSON JR, McDANIEL ML, 1992. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 41: 552-556.
12. CRYSTAL GJ, GUREVICIUS J, 1996. Nitric oxide does not modulate myocardial contractility acutely in in situ canine hearts. Am J Physiol 270: H1568-H1576.
13. FINKEL MS, ODDIS CV, MAYER OH, HATTLER BG, SIMMONS RL, 1995. Nitric oxide synthase inhibitor alters papillary muscle force-frequency relationship. J Pharmacol Exp Ther 272: 945-952.
14. GEORGE EE, ROMANO FD, DOBSON JG, 1991. Adenosine and acetylcholine reduce isoproterenol-induced protein phosphorylation of rat myocytes. J Mol Cell Cardiol 23: 749-764.
15. GRIFFITH OW, STUEHR J, 1995. Nitric oxide synthases: properties and catalytic mechanism. Ann Rev Physiol 57: 707-736.
16. HARDING P, CARRETERO OA, LAPOINTE MC, 1995. Effects of interleukin-1β and nitric oxide on cardiac myocytes. Hypertension 25: 421-430.
17. HARE JM, KEANEY JF, BALLIGAND JL, LOSCALZO J, SMITH TW, COLUCCI WS, 1995. Role of nitric oxide in parasympathetic modulation of β-adrenergic myocardial contractility in normal dogs. J Clin Invest 95: 360-366.
18. HAYAKAWA H, RAIJ L, 1997. The link among nitric oxide synthase activity, endothelial function, and aortic and ventricular hypertrophy in hypertension. Hypertension 29: 235-241.
19. HELLER BA, PAULSON DJ, KOPP SJ, PEACE DG, TOW JUNE, 1988. Depressed in vivo myocardial reactivity to dobutamine in streptozotocin diabetic rat: influence of exercise training. Cardiovasc Res 22: 417-424.
20. 2+ transport, fatty acid profiles and ultrastructure of isolated rat ventricular myocytes. Pflügers Arch 411: 564-572.
21. Gnitro-L-arginine, and aminoguanidine on constitutive and inducible nitric oxide synthase in rat aorta. Biochem Biophys Res Comm 199: 147-154.
22. KANEKO H, ENDO T, KIUCHI K, HAYAKAWA H, 1996. Inhibition of nitric oxide synthesis reduces coronary blood flow response but does not increase cardiac contractile response to β-adrenergic stimulation in normal dogs. J Cardiovasc Pharmacol 27: 247-254.
23. KAYE DM, WIVIOTT SD, BALLIGAND JL, SIMMONS WW, SMITH TW, KELLY RA, 1996. Frequency-dependent activation of a constitutive nitric oxide synthase and regulation of contractile function in adult rat ventricular myocytes. Circ Res 78: 217-224.
24. KELLY RA, BALLIGAND JL, SMITH TW, 1996. Nitric oxide and cardiac function. Circ Res 79: 363-380.
25. G-methyl-L-arginine decreases contractility, cGMP and cAMP in isoproterenol-stimulated rat hearts in vitro. Eur J Pharmacol 223: 1-7.
26. KOJDA G, KOTTENBERG K, NIX P, SCHLUTER KD, PIPER HM, NOACK E, 1996. Low increase in cGMP induced by organic nitrates and nitrovasodilators improves contractile response of rat ventricular myocytes. Circ Res 78: 91-101.
27. 2+ handling in ventricular myocytes isolated from diabetic rats. Am J Physiol 270: H1529-H1537.
28. ω-nitro-L-arginine methyl ester reduces the incidence of IDDM in BB/E rats. Diabetes 44: 365-368.
29. 2+ current. J Biol Chem 268: 26286-26295.
30. NATHAN C, XIE Q, 1994. Regulation of biosynthesis of nitric oxide. J Biol Chem 269: 13725-13728.
31. NAVA E, NOLL G, LUSCHER TF, 1995. Increased activity of constitutive nitric oxide synthase in cardiac endothelium in spontaneous hypertension. Circulation 91: 2310-2313.
32. NISHIO Y, KASHIWAGI A, KIDA Y, ABE N, SAEKI Y, KODAMA M, SHIGETA Y, 1988. Deficiency of cardiac β-adrenergic receptor in streptozotocin-induced diabetic rats. Diabetes 37: 1181-1187.
33. NORTON GR, CANDY G, WOODIWISS AJ, 1996. Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation 93: 1905-1912.
34. ODDIS CV, FINKEL MS, 1995. Cytokine-stimulated nitric oxide production inhibits mitochondrial activity in cardiac myocytes. Biochem Biophys Res Comm 213: 1002-1009.
35. OKAYAMA H, HAMADA M, HIWADA K, 1994. Contractile dysfunction in the diabetic-rat heart is an intrinsic abnormality of the cardiac myocytes. Clin Science 86: 257-262.
36. PAULSON DJ, CRASS MF III, 1982. Endogenous triacylglycerol metabolism in the diabetic heart. Am J Physiol 242: H1084-H1094.
37. PAULSON DJ, KOPP SJ, Tow JP, FELIKSIK JM, PEACE DG, 1986. Impaired in vivo myocardial reactivity to norepinephrine in diabetic rats. Proc Soc Exp Biol and Med 183: 186-192.
38. PINSKY DJ, CAI B, YANG X, RODRIGUEZ C, SCIACCA RR, CANNON PJ, 1995. The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor β. J Clin Invest 95: 677-685.
39. REES DD, PALMER RMJ, SCHULZ R, HUDSON HF, MONCADA S, 1990. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 101: 746-752.
40. ROBERTS AB, VODOVOTZ Y, ROCHE NS, SPORN MB, NATHAN CF, 1992. Role of nitric oxide in antagonistic effects of transforming growth factor-β and interleukin-1β on the beating rate of cultured cardiac myocytes. Endocrinology 6: 1921-1930.
41. RODRIGUES B, MCNEILL JH, 1992. The diabetic heart: metabolic causes for the development of a cardiomyopathy. Cardiovasc Res 26: 913-922.
42. ROZANSKI GJ, WITT RC, 1994. IL-1 inhibits β-adrenergic control of cardiac calcium current: role of L-arginine/ nitric oxide pathway. Am J Physiol 267: H1753-H1758.
43. 2+-independent nitric oxide synthase in the myocardium. Br J Pharmacol 105: 575-580.
44. 2+ in intact cardiac myocytes. Circ Res 74: 970-978.
45. SONNENBLICK EH, FRISHMAN WH, LEJEMTEL TH, 1979. Dobutamine: a new synthetic cardioactive sympathetic amine. N Engl J Med 300: 17-22.
46. STAMBLER JS, 1994. Redox signaling: nitrosylation and related target interactions of nitric oxide. Cell 78: 931-936.
47. TAHILIANI AG, MCNEILL JH, 1986. Minireview: diabetes-induced abnormalities in the myocardium. Life Sci 38: 959-974.
48. TAO S, MCKENNA TM, 1994. In vitro endotoxin exposure induces contractile dysfunction in adult rat cardiac myocytes. Am J Physiol 267: H1745-H1752.
49. TILTON RG, CHANG K, HASAN KS, SMITH SR, PETRASH JM, MISKO TP, MOORE WM, CURRIE MG, CORBETT JA, MCDANIEL ML, WILLIAMSON JR, 1993. Prevention of diabetic vascular dysfunction by guanidines: inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 42: 221-232.
50. TOMLINSON KC, GARDINER SM, HEBDEN RA, BENNETT T, 1992. Functional consequences of streptozotocin-induced diabetes mellitus, with particular reference to the cardiovascular system. Pharmacol Rev 44: 103-150.
51. TSUCHIDA K, WATAJIMA H, OTOMO S, 1994. Calcium current in rat diabetic ventricular myocytes. Am J Physiol 267: H2280-H2289.
52. TSUJINO M, HIRATA Y, IMAI T, KANNO K, EGUCHI S, ITO H, MARUMO F, 1994. Induction of nitric oxide synthase gene by interleukin-1β in cultured rat cardiocytes. Circulation 90: 375-383.
53. UNGUREANU-LONGROIS D, BALLIGAND JL, OKADA I, SIMMONS WW, KOBZIK L, LOWENSTEIN CJ, KUNKEL SL, MICHEL T, KELLY RA, SMITH TW, 1995. Contractile responsiveness of ventricular myocytes to isoproterenol is regulated by induction of nitric oxide synthase activity in cardiac microvascular endothelial cells in heterotypic primary culture. Circ Res 77: 486-493.
54. WAHLER GM, DOLLINGER SJ, 1995. Nitric oxide donor SIN-1 inhibits mammalian cardiac calcium current through cGMP-dependent protein kinase. Am J Physiol 268: C45-C54.
55. 2+ currents in ventricular myocytes from rats with chronic diabetes. Am J Physiol 269: H1288-H1296.
56. G-monomethyl-L-arginine on the onset of diabetes in the spontaneously diabetic BB rat. Diabetes 44: 360-364.
57. YANG X, CHOWDHURY N, CAI B, BRETT J, MARBOE C, SCIACCA RR, MICHIER RE, CANNON PJ, 1994. Induction of myocardial nitric oxide synthase by cardiac allograft rejection. J Clin Invest 94: 714-721.
58. i responses to isoproterenol and cAMP in isolated cardiomyocytes from experimental diabetic rats. Am J Physiol 266: H2334-H2342.
59. YU Z, TIBBITS GF, MCNEILL JH, 1994b. Cellular functions of diabetic cardiomyocytes: contractility, rapid-cooling contracture, and ryanodine binding. Am J Physiol 266: H2082-H2089.